Metoprolol Succinat Teva

Metoprolol succinate, the active ingredient in Metoprolol Succinate Teva, is a beta blocker presented as an oral tablet for oral administration. It is indicated for the treatment of hypertension, angina pectoris, chronic heart failure, post‑myocardial infarction care, and certain cardiac arrhythmias, helping to lower heart rate and reduce cardiac workload.

GNH USA supplies Metoprolol Succinate Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑origin manufacturing base. The company also supports regulatory compliance for each market.

Metoprolol succinate is a selective β1‑adrenergic blocker used in cardiovascular disease management. - Hypertension: reduces blood pressure by decreasing cardiac output and renin release. - Angina pectoris: alleviates chest pain by lowering myocardial oxygen demand. - Chronic heart failure: improves survival and reduces hospitalizations by decreasing heart rate and workload. - Post‑myocardial infarction: lowers risk of recurrent events through heart rate control. - Cardiac arrhythmias: stabilizes heart rhythm by suppressing abnormal β‑adrenergic activity.

Metoprolol succinate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially when standing quickly. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea, abdominal discomfort or constipation. - Sleep disturbances: insomnia or vivid dreams.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: impairment of electrical conduction in the heart. - Hypotension: dangerously low blood pressure. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Depression or mood changes: new or worsening depressive symptoms. - Heart failure exacerbation: worsening of existing heart failure symptoms.

When prescribing metoprolol succinate, clinicians should consider several precautionary measures to ensure safe use. - Dose titration: start low and adjust gradually based on blood pressure and heart rate. - Cardiovascular monitoring: regularly assess heart rate, blood pressure, and signs of heart failure. - Respiratory caution: avoid in patients with severe asthma or chronic obstructive pulmonary disease. - Diabetes management: monitor blood glucose as β‑blockade may mask hypoglycemia symptoms. - Drug discontinuation: do not stop abruptly; taper to prevent rebound tachycardia or hypertension. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol succinate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of severe bradycardia and AV block. - Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycemia signs.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs, diuretics): may enhance blood pressure lowering. - Antidepressants (SSRIs, SNRIs): potential for increased plasma levels of metoprolol. - CYP2D6 inhibitors (paroxetine, fluoxetine): can raise metoprolol concentrations.